Iradimed Co (IRMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 11:05 AM ET
Iradimed Co (IRMD) Earnings: Report Dates and Results
Iradimed (IRMD) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Iradimed reported EPS of $0.51, below the $0.52 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IRMD has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.0% above the $0.54 reported for the quarter ended Dec 31, 2025.
IRMD Earnings Call
The latest IRMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, IRMD beat 33, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $24.20M, up 14.2% from $21.20M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.51 | $0.52 | N/A | -1.92% | Miss | +8.5% | 3 | 1 up, 0 down | Oct 30, 2026 | $24.20M |
| Jun 30, 2026 | $0.41 | $0.42 | N/A | -2.38% | Miss | -16.3% | 2 | 0 up, 1 down | Jul 31, 2026 | $20.47M |
| Mar 31, 2026 | $0.49 | $0.45 | $0.44 - $0.45 | +8.89% | Beat | +16.7% | 2 | 0 up, 1 down | May 1, 2026 | $21.98M |
| Dec 31, 2025 | $0.54 | $0.48 | $0.47 - $0.49 | +12.50% | Beat | +35.0% | 2 | 0 up, 0 down | Feb 10, 2026 | $22.69M |
| Sep 30, 2025 | $0.47 | $0.46 | $0.45 - $0.46 | +2.17% | Beat | +9.3% | 2 | 0 up, 0 down | Nov 3, 2025 | $21.20M |
| Jun 30, 2025 | $0.49 | $0.44 | $0.42 - $0.45 | +11.36% | Beat | +16.7% | 2 | 1 up, 1 down | Aug 1, 2025 | $20.41M |
| Mar 31, 2025 | $0.42 | $0.41 | $0.39 - $0.43 | +2.44% | Beat | +16.7% | 2 | 1 up, 1 down | May 5, 2025 | $19.51M |
| Dec 31, 2024 | $0.40 | $0.41 | N/A | -2.44% | Miss | +2.6% | 2 | 1 up, 0 down | Feb 13, 2025 | $19.39M |
| Sep 30, 2024 | $0.43 | $0.39 | $0.38 - $0.39 | +10.26% | Beat | 0.0% | 2 | 0 up, 0 down | Oct 31, 2024 | $18.33M |
| Jun 30, 2024 | $0.42 | $0.37 | $0.36 - $0.37 | +13.51% | Beat | +16.7% | 2 | 0 up, 0 down | Aug 1, 2024 | $17.93M |
| Mar 31, 2024 | $0.36 | $0.34 | $0.33 - $0.34 | +5.88% | Beat | +20.0% | 2 | 0 up, 1 down | May 2, 2024 | $17.60M |
| Dec 31, 2023 | $0.39 | $0.38 | $0.38 - $0.41 | +2.63% | Beat | +21.9% | 3 | 0 up, 0 down | Feb 8, 2024 | $17.45M |
| Sep 30, 2023 | $0.43 | $0.37 | $0.36 - $0.37 | +16.22% | Beat | +48.3% | 3 | 0 up, 0 down | Nov 3, 2023 | $16.50M |
| Jun 30, 2023 | $0.36 | $0.31 | $0.30 - $0.32 | +16.13% | Beat | +38.5% | 3 | 0 up, 0 down | Aug 3, 2023 | $16.13M |
| Mar 31, 2023 | $0.30 | $0.27 | $0.26 - $0.32 | +11.11% | Beat | +36.4% | 3 | 0 up, 0 down | May 4, 2023 | $15.48M |
| Dec 31, 2022 | $0.32 | $0.31 | $0.29 - $0.31 | +3.23% | Beat | -3.0% | 2 | 1 up, 0 down | Feb 2, 2023 | $14.86M |
| Sep 30, 2022 | $0.29 | $0.24 | $0.24 - $0.25 | +20.83% | Beat | +26.1% | 2 | 0 up, 0 down | Nov 3, 2022 | $13.41M |
| Jun 30, 2022 | $0.26 | $0.24 | $0.23 - $0.24 | +8.33% | Beat | +85.7% | 2 | 0 up, 0 down | Jul 29, 2022 | $12.72M |
| Mar 31, 2022 | $0.22 | $0.21 | $0.20 - $0.21 | +4.76% | Beat | +69.2% | 2 | 0 up, 0 down | Apr 29, 2022 | $12.31M |
| Dec 31, 2021 | $0.33 | $0.21 | $0.21 - $0.21 | +57.14% | Beat | +371.4% | 2 | 0 up, 0 down | Feb 4, 2022 | $11.87M |
| Sep 30, 2021 | $0.23 | $0.17 | $0.17 - $0.17 | +35.29% | Beat | +109.1% | 2 | 0 up, 0 down | Oct 29, 2021 | $10.91M |
| Jun 30, 2021 | $0.14 | $0.15 | $0.04 - $0.15 | -6.67% | Miss | +180.0% | 2 | N/A | Jul 30, 2021 | $9.81M |
| Mar 31, 2021 | $0.13 | $0.09 | $0.09 - $0.11 | +44.44% | Beat | -27.8% | 2 | N/A | Apr 30, 2021 | $9.22M |
| Dec 31, 2020 | $0.07 | $0.09 | $0.09 - $0.12 | -22.22% | Miss | -76.7% | 2 | N/A | Feb 4, 2021 | $8.55M |
| Sep 30, 2020 | $0.11 | $0.05 | $0.05 - $0.15 | +120.00% | Beat | -52.2% | 2 | N/A | Oct 30, 2020 | $7.70M |
| Jun 30, 2020 | $0.05 | -$0.04 | -$0.04 - $0.03 | +225.00% | Beat | -75.0% | 2 | N/A | Jul 30, 2020 | $6.79M |
| Mar 31, 2020 | $0.18 | $0.12 | $0.12 - $0.18 | +50.00% | Beat | +38.5% | 2 | N/A | Apr 30, 2020 | $8.68M |
| Dec 31, 2019 | $0.30 | $0.20 | $0.20 - $0.21 | +50.00% | Beat | +87.5% | 2 | N/A | Feb 6, 2020 | $10.89M |
| Sep 30, 2019 | $0.23 | $0.15 | N/A | +53.33% | Beat | +64.3% | 2 | N/A | Oct 30, 2019 | $9.96M |
| Jun 30, 2019 | $0.20 | $0.15 | $0.15 - $0.15 | +33.33% | Beat | +42.9% | 1 | N/A | Jul 30, 2019 | $9.23M |
| Mar 31, 2019 | $0.13 | $0.13 | $0.13 - $0.17 | 0.00% | In line | +30.0% | 2 | N/A | Apr 30, 2019 | $8.44M |
| Dec 31, 2018 | $0.16 | $0.13 | $0.13 - $0.13 | +23.08% | Beat | +60.0% | 2 | N/A | Feb 6, 2019 | $8.34M |
| Sep 30, 2018 | $0.14 | $0.10 | $0.10 - $0.10 | +40.00% | Beat | +100.0% | 2 | N/A | Oct 30, 2018 | $7.61M |
| Jun 30, 2018 | $0.14 | $0.10 | $0.10 - $0.10 | +40.00% | Beat | +133.3% | 2 | N/A | Jul 31, 2018 | $7.38M |
| Mar 31, 2018 | $0.10 | $0.06 | $0.06 - $0.06 | +66.67% | Beat | N/A | 2 | N/A | Apr 30, 2018 | $7.11M |
| Dec 31, 2017 | $0.10 | $0.06 | $0.05 - $0.06 | +66.67% | Beat | -9.1% | 2 | N/A | Feb 6, 2018 | $6.70M |
| Sep 30, 2017 | $0.07 | $0.03 | N/A | +133.33% | Beat | -50.0% | N/A | N/A | Oct 30, 2017 | $5.69M |
| Jun 30, 2017 | $0.06 | $0.01 | N/A | +500.00% | Beat | -75.0% | N/A | N/A | Jul 28, 2017 | $5.52M |
| Mar 31, 2017 | -$0.02 | $0.01 | N/A | -300.00% | Miss | -109.5% | N/A | N/A | Apr 28, 2017 | $5.16M |
| Dec 31, 2016 | $0.11 | $0.04 | N/A | +175.00% | Beat | -50.0% | N/A | N/A | Feb 6, 2017 | $5.99M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.92, up 19.3% from the year before. It was $0.70 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.92 | +19.3% |
| Dec 31, 2024 | $1.61 | +8.8% |
| Dec 31, 2023 | $1.48 | +35.8% |
| Dec 31, 2022 | $1.09 | +31.3% |
| Dec 31, 2021 | $0.83 | +102.4% |
| Dec 31, 2020 | $0.41 | -52.3% |
| Dec 31, 2019 | $0.86 | +59.3% |
| Dec 31, 2018 | $0.54 | +157.1% |
| Dec 31, 2017 | $0.21 | -70.0% |
| Dec 31, 2016 | $0.70 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,900 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,850 | 6 | |
| 2026Q2 | Jun 30, 2026 | 2,654 | 4 | |
| 2026Q1 | Mar 31, 2026 | 2,619 | 4 | |
| 2025Q4 | Dec 31, 2025 | 2,524 | 5 | |
| 2025Q3 | Sep 30, 2025 | 2,651 | 5 | |
| 2025Q2 | Jun 30, 2025 | 2,901 | 5 | |
| 2025Q1 | Mar 31, 2025 | 2,510 | 4 | |
| 2024Q4 | Dec 31, 2024 | 2,910 | 5 |
2026Q3 Earnings Call
Opening remarks
Roger Susi President and Chief Executive Officer Thank you. Good morning, and welcome to IRadimed's Third Quarter 2026 Earnings Call. I'm very proud to say that the new 3870 MR IV pump launch is showing itself to be everything we had hoped for and more. Though you may recall that we discussed the ramping of this new pump would be quite a stretch, we have been able to push very hard and make it happen. With our initial testing-of-the-waters release of a few dozen pumps during Q4 and Q1 to the broad market launch in Q2, and having produced now over 400 systems during Q3, our teams have risen to perform extraordinarily well. The job of ramping production of this complex electromechanical device at the rate achieved is a very difficult task, and these hard-working ladies and gentlemen of your company have really risen to the challenge. The ramp rate of the 3870 production to achieve Q3's revenue was huge, at over a 125% increase from Q2's production, thus the large stretch goal for production. And to support the goal was a great selling effort. Consider that during Q3, our sales team booked record numbers of both the 3880 monitor and 3870 pumps, proving the customer acceptance of these devices and building a very comfortable backlog for Q4. For Q4, we will again grow revenue of the new 3870 pump by another 50-plus percent. Again, very pleased to report that our teams have delivered. Here are the numbers. We achieved record quarterly revenue of $24.2 million, up 14% from Q3 of 2025 and an 18% sequential increase from Q2. Earnings were $0.51 per share GAAP and $0.55 non-GAAP, up from $0.41 and $0.46, respectively, in the second quarter. And as we expected, as our manufacturing teams climb the 3870 learning curve, we begin realizing efficiencies we had anticipated, with the gross margin improving 2 full points sequentially to 76%. Behind these quarter-end numbers is the performance of not only our production, engineering, quality and materials teams in-house, but our field sales team as well. We had concerns that the long-anticipated new 3870 pump could steal sales focus from the monitor, and so we put in place special targets to mitigate such an issue. Indeed, though Q1 did show weak monitor bookings, this was quickly turned around in Q2 with a record number of monitors booked, and we are once again extremely proud to note that record was exceeded again in Q3. In short, monitor sales are strong and growing. This is along with what is now clearly becoming a successful launch of the long-awaited 3870 MR IV pump.
Frequently Asked Questions About IRMD
When is Iradimed's next earnings date?
Iradimed's next earnings report is expected for Feb 8, 2027.
Did IRMD beat earnings estimates last quarter?
No. Iradimed reported EPS of $0.51 for the quarter ended Sep 30, 2026, below the $0.52 estimate by 1.92%.
What EPS do analysts expect from IRMD next quarter?
The consensus EPS estimate for Iradimed for the quarter ending Dec 31, 2026 is $0.61 from 5 analysts, with estimates from $0.58 to $0.64.
How often does IRMD beat earnings estimates?
Iradimed beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.83%.
IRMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts